The way this works for the year was simple, Genere

The way this works for the year was simple, Generex in January 2017 had all the assets and fan fodder, good bad or indifferent nothing has changed, 23 years public, hundreds of millions went into the company, and now hundreds of millions in NOL tax free cash, with that all said, now look what we’ve accomplished, cleaned up cap table, negotiated out all our old toxic note holders, cleaned up all the debt in the company, turned around negative shareholder equity from last k of approx -43 million to plus +13 mill last quarter as well as tangible assets huge increases, bought Hema diagnostics, Veneto MSO, pharmacies, Regentys, Olaregen, Medisource and Pantheon, with many other opportunities as said publicly, did a success dividend to shareholders which during the acquisitions gave shareholders 20+ the one share they had bringing the stock to a high of approx 26.00 a share finally paying that success dividend at 18.99 a share and the following day being auto adjusted because the regulators treated it like a forward split which opened us up at .83 cents approx which then we surged to 3.10 giving shareholders who were in at 1.60/80 a share in June/July 2018 a 61.00 cost bases and share value structure, and today at 2.20 a cost basis of 44.00 approx a share, with an approx 2000 percent move for the year, and now application to Nasdaq is in process and been paid to the Nasdaq their fee, and one more success dividend has been called for. If this is not success in the markets I don’t know what is, remember before January Generex was a dormant out of business company with no one other then the CEO praying for a miracle and an exit out!